CRLCollaboration•businesswire•
Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer
Sentiment:Positive (65)
Summary
(NYSE:CRL) WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River collaborates to enhance oncology manufacturing portfolio by advancing development of cell and gene therapies to treat cancer.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 11, 2025 by businesswire